AstraZeneca PLC AstraZeneca divests rights to Seroquel and (5420R)

TIDMAZN

RNS Number : 5420R

AstraZeneca PLC

30 October 2019

30 October 2019 07:00 GMT

AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia

Sale to Cheplapharm supports AstraZeneca's focus on main therapy areas

AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in Europe and Russia.

Ruud Dobber, Executive Vice President, Biopharmaceuticals, said: "Seroquel is an important established medicine and this agreement with Cheplapharm will help ensure continued patient access. It forms part of our strategy of reducing the portfolio of mature medicines to enable reinvestment in our main therapy areas."

AstraZeneca will continue to manufacture and supply Seroquel and Seroquel XR to Cheplapharm during a transition period.

Pursuant to Listing Rule 10.4.1R (notification of class 2 transactions), the gross book value of assets subject to the divestment as at 31 December 2018 was nil. In the year to 31 December 2018, the aggregate pre-tax profits attributable to Seroquel and Seroquel XR in the relevant territories were $86m. The consideration will be paid in cash and the proceeds used for general corporate purposes.

Financial considerations

Cheplapharm will make an upfront payment of $178m to AstraZeneca and may also make future sales-contingent payments of up to $61m. Income arising from the upfront and future payments will be reported in AstraZeneca's financial statements within Other Operating Income & Expense. In 2018, Seroquel generated annual product sales of $47m in the markets covered by this agreement, while Seroquel XR generated $61m. The agreement does not impact the Company's financial guidance for 2019. The transaction is expected to complete in the fourth quarter of 2019, subject to customary closing conditions and regulatory clearances.

About Seroquel

Seroquel and Seroquel XR are atypical anti-psychotic medicines with antidepressant properties. The main indications for Seroquel are the treatment of schizophrenia and bipolar disorder. Seroquel XR is also approved in some markets for major depressive disorder and generalised anxiety disorder.

AstraZeneca has previously disposed of the rights to Seroquel and Seroquel XR in the UK, Japan and other major international markets.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 
 Media Relations 
 Gonzalo Viña                                                             [phone] 
 Rob Skelding                           Oncology                               [phone] 
 Rebecca Einhorn                        Oncology                                [phone] 
 Matt Kent                              BioPharmaceuticals                     [phone] 
 Jennifer Hursit                        Other                                  [phone] 
 Christina Malmberg Hägerstrand    Sweden                                 [phone] 
 Michele Meixell                        US                                      [phone] 
 
 Investor Relations 
 Thomas Kudsk Larsen                                                           [phone] 
 Henry Wheeler                          Oncology                               [phone] 
 Christer Gruvris                       BioPharmaceuticals (CV, Metabolism)    [phone] 
 Nick Stone                             BioPharmaceuticals (Renal), ESG        [phone] 
                                        BioPharmaceuticals (Respiratory), 
 Josie Afolabi                           other medicines                       [phone] 
 Craig Marks                            Finance, fixed income                  [phone] 
 Jennifer Kretzmann                     Corporate access, retail investors     [phone] 
 US toll-free                                                                  [phone] 
 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCKMMZGLLNGLZM

(END) Dow Jones Newswires

October 30, 2019 03:00 ET (07:00 GMT)